Conference Coverage

Sulforaphane for autism? Maybe


 

REPORTING FROM AAN 2018

The randomized portion is still blinded. But so far, 31% have responded positively at 15 weeks, meaning a much or very much improved score in at least two domains on the Ohio Autism Clinical Global Impressions Scale; domains cover social interaction, violent behavior, communication, and other areas.

Among the patients who have completed the study, the response rate at week 30 almost doubled, to 56%. “We don’t know which patients were on sulforaphane and which were on placebo” in the randomized phase, Dr. Singh said. “But we think because the response doubled” when the second half of the children were switched to sulforaphane, “there should probably not be a very large placebo effect here.”

Meanwhile, after the washout period, “some patients still do well, but many more [go] back to baseline,” added Dr. Singh, the senior investigator in the new trial.


The most common side effects are insomnia (28%), vomiting (19%), flatulence (17%), diarrhea (15%), and constipation (13%). A few patients have dropped out because of insomnia and diarrhea; more have dropped out because they simply didn’t want to take the pills – 125 mg of broccoli seed powder three to eight times a day, depending on weight.

Recommended Reading

Which infants with invasive bacterial infections are at risk for adverse outcomes?
MDedge Family Medicine
Simple QI intervention helped improve HPV vaccination rates
MDedge Family Medicine
Pediatric cancers are on the rise
MDedge Family Medicine
No-shows
MDedge Family Medicine
Guidelines-based intervention improves pediatrician management of acne
MDedge Family Medicine
The double-edged sword
MDedge Family Medicine
Trends in teen consumption of sports drinks are up and down
MDedge Family Medicine
Drug-related deaths continue to rise in United States
MDedge Family Medicine
Behavioral sleep intervention linked to sleep improvement in infants
MDedge Family Medicine
HBV birth dose predicts vaccine adherence
MDedge Family Medicine